

- European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). *Eur J Cardiovasc Prev Rehabil* 2003;10:S1–S10.
2. Rosenson RS. Current overview of statin-induced myopathy. *Am J Med* 2004;116:408–416.
 3. Eriksson M, Angelin B, Sjöberg S. Risk for fatal stain-induced rhabdomyolysis as a consequence of misinterpretation of ‘evidence-based medicine’. *J Intern Med* 2005;257:313–314.
 4. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. *Muscle Nerve* 2005;31:572–580.
 5. Prasad GV, Wong T, Meliton G et al. Rhabdomyolysis due to red yeast rice (*Monascus purpureus*) in a renal transplant recipient. *Transplantation* 2002;27:1200–1201.
 6. Smith DJ, Olive KE. Chinese red rice-induced myopathy. *South Med J* 2003;96:1265–1267.
 7. Rundek T, Naini A, Sacco R et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889–892.
 8. Yang HT, Lin SH, Huang SY et al. Acute administration of red yeast rice (*Monascus purpureus*) depletes tissue coenzyme Q (10) levels in ICR mice. *Br J Nutr* 2005;93:131–135.

MEDICATION APPROPRIATENESS INDEX: RELIABILITY AND RECOMMENDATIONS FOR FUTURE USE

To the Editor: The Medication Appropriateness Index (MAI) measures the appropriateness of prescribing for elderly patients, using 10 criteria for each medication prescribed. For each criterion, the evaluator rates whether the medication is appropriate, marginally appropriate, or inappropriate. Support is provided through explicit definitions and instructions.¹ The MAI has been used in observational and interventional studies.^{2–6} Its feasibility, content validity, predictive validity, and reliability have been demonstrated in ambulatory settings.^{1,7–10} Its limitations are that reliability was lower when assessed by researchers different from the authors^{9,10} and that the original instrument does not address some areas (drug allergy, adverse drug reactions, compliance). We wanted to assess the reliability of the MAI for elderly patients hospitalized on a Belgian geriatric unit. Professionals with expertise in geriatrics but practicing on different sites were involved. Similar to previous research,⁹ this study proceeded in two phases. First, the MAI was translated into French and piloted by a clinical pharmacist on 10 patients. Following discussions with another clinical pharmacist and a geriatrician, clarifications were introduced in the instructions. Second, interrater reliability between a clinical pharmacist (AS) and a geriatrician (CD) was checked, using 113 drugs prescribed to 16 patients at discharge (69% female, mean age 79.6, mean number of prescribed drugs on admission 6.2). The raters used an abstracted patient chart compounded by the clinical pharmacist (using data from the medical record and patient interview and from contact with the general practitioner or the community pharmacist if needed). Both raters performed the evaluations independently and then met to compare their ratings. Discrepancies were discussed, and raters were allowed to change their ratings to reach a consensus. Table 1 summarizes the results of agreement before and after discussion. Overall agreement was good and improved after discussion. Agreement on interactions was unsatisfactory before discussion between raters. Insufficient or unclear instructions in the

MAI were found to be an important source of discrepancies. Based on this and on previous similar experience,^{8–10} the following suggestions that might enhance the validity and reliability of the instrument are made.

General suggestions:

Add examples of appropriate, moderately appropriate, and inappropriate prescribing that are relevant to the geriatric population.

Define “moderately appropriate” for all criteria.

Consider how compliance could be accounted for, for example with regard to choice (e.g., is the choice appropriate in a patient unwilling to take his or her medicines) or to practical directions (e.g., evidence that the patient does not take the medication).

Suggestions specific to individual criteria:

- **Indication:**
Add instruction that “global status” should be taken into account (e.g., vitamin D in a patient with previous fractures but in palliative care is not always a valid indication).
 - **Choice:**
Clarify how to cope with cases in which choice is inappropriate because of drug–drug or drug–disease interactions (e.g., use of alendronate in a patient with severe esophagitis; is it considered inappropriate in terms of choice and/or of drug–disease interaction?).
 - **Dosage:**
When a dose has been recently modified but consequences are not yet measurable, specify that clinical judgment should be used instead of the evaluation tool provided in the instrument.
- Replace the 1997 Beers list with the 2003 updated list.
- **Modalities correct**
The directions (regarding food and time of administration) provided for a limited number of drugs should be completed to include directions for additional drugs commonly prescribed in geriatrics.
 - **Modalities practical**
Take into account the information provided to the patient to ensure adequate intake of the medication; give inappropriate ratings when written instructions for a new medicine with specific modalities of administration (e.g., bisphosphonates) are not provided.
 - **Drug–drug and drug–disease interactions**
Further investigate interrater reliability, because low prevalence precluded a complete analysis in previous reports,^{1,8,10} and prevalence was higher in the current study, but initial reliability was unsatisfactory.
- Review the modifications proposed previously,^{8,9} and agree on the definition to use in each setting.
- Update the list of drug–disease interactions provided in the instrument. (Some may not be clinically relevant anymore.)
- Include allergy as a drug–disease interaction.
- **Duration**
Add specific instructions for drugs that are progressively withdrawn.

Table 1. Interrater Reliability Between a Clinical Pharmacist and a Geriatrician (n = 113 Drugs Prescribed to 16 Patients at Hospital Discharge)

Parameter	A	B	C	D	Positive Predictive Value	Negative Predictive Value	Kappa*
Before discussion between raters							
Indication	104	6	0	3	0.97	0.5	0.48
Effectiveness	93	6	2	12	0.96	0.75	0.71
Dosage	90	6	6	11	0.93	0.65	0.58
Correct directions	92	5	3	13	0.96	0.76	0.72
Practical directions	94	7	4	8	0.94	0.59	0.54
Drug–drug interaction	91	16	4	2	0.90	0.20	0.09
Drug–disease interaction	86	19	2	6	0.89	0.36	0.29
Duplication	106	0	0	7	1.00	1.00	1.00
Duration	94	5	1	13	0.97	0.81	0.78
Overall†	49	11	4	49	0.87	0.87	0.74
After discussion between raters							
Indication	106	1	0	6	1.00	0.92	0.92
Effectiveness	94	2	1	16	0.98	0.91	0.90
Dosage	92	1	3	17	0.98	0.89	0.87
Correct directions	95	0	2	16	0.99	0.94	0.93
Practical directions	97	4	1	11	0.97	0.81	0.79
Drug–drug interaction	95	10	0	8	0.95	0.62	0.57
Drug–disease interaction	92	8	0	13	0.96	0.76	0.73
Duplication	106	0	0	7	1.00	1.00	1.00
Duration	95	1	0	17	0.99	0.97	0.97
Overall†	50	7	2	54	0.92	0.92	0.84

Note: Cost (10th criterion) was not included in the analysis, because an explicit source for comparing the costs of drugs in Belgium was used instead.

*A kappa statistic of 0.40–0.75 denotes good interrater reliability, and a kappa value >0.75 denotes excellent reproducibility.

†Drug's overall appropriateness (inappropriate if ≥ 1 of the 10 items were rated as inappropriate).

A = appropriate according to both raters; B = appropriate according to clinical pharmacist, inappropriate according to geriatrician; C = appropriate according to geriatrician, inappropriate according to clinical pharmacist; D = inappropriate according to both raters.

Consider giving (moderately) inappropriate rating for short-term treatments for which no indication on the end of treatment has been provided in the letter or to the patient.

In conclusion, even though perfect interrater agreement is illusory, additional instructions and examples could improve the validity and reliability of the instrument. Researchers with previous experience with the MAI could discuss this.

Anne Spinewine, MSc
Center for Clinical Pharmacy
Université Catholique de Louvain
Louvain, Belgium

Christophe Dumont, MD
Department of Internal Medicine and Geriatrics
Hopitaux St. Joseph-St. Therese-IMTR
Gilly, Belgium

Louise Mallet, PharmD
Faculty of Pharmacy
Université de Montréal
McGill University Health Center
Montréal, Québec, Canada

Christian Swine, MD
Center for Clinical Pharmacy

Université Catholique de Louvain
Louvain, Belgium
Department of Geriatrics
Mont-Godinne University Hospital
Yvoir, Belgium

ACKNOWLEDGMENTS

Financial Disclosure: Anne Spinewine is a Research Fellow of the Belgian Fonds National de la Recherche Scientifique.

Author Contributions: A. Spinewine participated in study design, acquisition of data, analysis and interpretation of data, and preparation of the manuscript. C. Dumont participated in analysis and interpretation of data and preparation of the manuscript. L. Mallet participated in analysis and interpretation of data. C. Swine participated in study design, analysis and interpretation of data, and preparation of the manuscript.

Sponsor's Role: None.

REFERENCES

- Hanlon JT, Schmader KE, Samsa GP et al. A method for assessing drug therapy appropriateness. *J Clin Epidemiol* 1992;45:1045–1051.
- Hanlon JT, Weinberger M, Samsa GP et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. *Am J Med* 1996;100:428–437.
- Schmader K, Hanlon JT, Weinberger M et al. Appropriateness of medication prescribing in ambulatory elderly patients. *J Am Geriatr Soc* 1994;42:1241–1247.

4. Schmader KE, Hanlon JT, Pieper CF et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. *Am J Med* 2004;116:394–401.
5. Hajjar ER, Hanlon JT, Sloane RJ et al. Unnecessary drug use in frail older people at hospital discharge. *J Am Geriatr Soc* 2005;53:1518–1523.
6. Crotty M, Rowett D, Spurling L et al. Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. *Am J Geriatr Pharmacother* 2004;2:257–264.
7. Samsa GP, Hanlon JT, Schmader KE et al. A summated score for the medication appropriateness index: Development and assessment of clinimetric properties including content validity. *J Clin Epidemiol* 1994;47:891–896.
8. Fitzgerald LS, Hanlon JT, Shelton PS et al. Reliability of a modified medication appropriateness index in ambulatory older persons. *Ann Pharmacother* 1997;31:543–548.
9. Kassam R, Martin LG, Farris KB. Reliability of a modified medication appropriateness index in community pharmacies. *Ann Pharmacother* 2003;37:40–46.
10. Bregnhøj L, Thirstrup S, Kristensen MB et al. Reliability of a modified medication appropriateness index in primary care. *Eur J Clin Pharmacol* 2005;61:769–773.

PLEURODESIS WITH CARBOPLATIN IN ELDERLY PATIENTS WITH MALIGNANT PLEURAL EFFUSION AND LUNG ADENOCARCINOMA

To the Editor: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths in industrialized countries. Pleuritis carcinomatosa and malignant pleural effusion (MPE) sometimes accompany the peripheral type of adenocarcinoma of NSCLC.¹ MPE that is poorly controlled by systemic chemotherapy is often treated with pleurodesis using intrapleural injection of OK-432² or cisplatin³ as irritants to create inflammation, which tacks the two pleura together and prevents the reaccumulation of fluid. Treatment with cisplatin for MPE is effective and results in good long-term control of respiratory symptoms such as dyspnea on exertion,³ but treatment with OK-432 often brings about persistent fever or chest pain, which further decreases quality of life in elderly patients with NSCLC.² Furthermore, pleurodesis with cisplatin needs sufficient hydration to avoid direct renal damage by cisplatin and is prohibited in patients with renal insufficiency or heart failure.⁴ Alternatively, carboplatin, a derivative of platinum, has lower toxicity to renal function than cisplatin and can be used in patients with renal insufficiency with a calculated dose using the Calvert formula,⁵ although pleurodesis with carboplatin for MPE in elderly patients with renal insufficiency has not been reported.

Pleurodesis using carboplatin was performed to control MPE accompanied by lung adenocarcinoma in three elderly patients with poor performance status and renal insufficiency suffering from dyspnea between June 2000 and January 2005, as shown in Table 1. The staging of primary lung cancer was determined using computed tomography scans of the brain, chest, and abdomen; a positron emission tomography scan; and a Technetium-99m scintigram of the bone. Performance status was rated using the Eastern Cooperative Oncology Group scale.⁶ The lung cancer cell type was determined using histological or cytological diagnosis using bronchoscopy or thoracic puncture. Renal function was assessed using a 24-hour creatinine clearance test to estimate the dose of carboplatin before pleurodesis. Fur-

Table 1. Characteristics of the Patients

Case	Age	Sex	Cell Type	Stage (TNM Classification)	Performance Status	Dose of Carboplatin (mg)	Dose of Hydration (mL)	24-Hour Creatinine Clearance (mL/min)	Serum Creatinine Before Treatment	Serum Creatinine After Treatment	Time to Progression Regarding Malignant Pleural Effusion (Days)
1	79	Female	Adenocarcinoma	III B (T4N0M0)	3	300	550	35	2.2	2.1	212
2	88	Male	Adenocarcinoma	III B (T4N3M0)	4	425	500	60	1.1	1.2	128
3	77	Female	Adenocarcinoma	III B (T4N2M0)	3	400	550	55	1.3	1.3	94

Note: Serum creatinine values were measured before and 72 hours after treatment with pleurodesis using carboplatin.